MAP Kinase Kinase 1

• 

  Subject Areas on Research

  • A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. 
  • Activation of the 9E3/cCAF chemokine by phorbol esters occurs via multiple signal transduction pathways that converge to MEK1/ERK2 and activate the Elk1 transcription factor. 
  • Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. 
  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. 
  • Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. 
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. 
  • Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases. 
  • Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. 
  • In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. 
  • Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. 
  • Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. 
  • Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. 
  • Ligation of the alpha2M* signaling receptor regulates synthesis of cytosolic phospholipase A2. 
  • MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. 
  • MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease. 
  • Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. 
  • Negative regulation of mTOR activation by diacylglycerol kinases. 
  • Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. 
  • Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. 
  • Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. 
  • Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos. 
  • Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. 
  • UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. 
  • Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. 
  • mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.